Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can six short writing sessions ease PTSD in underserved patients?

NCT ID NCT05330442

Symptom relief Sponsor: RAND Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether Written Exposure Therapy (WET), a brief six-session therapy involving guided writing about a traumatic event, can reduce PTSD symptoms in adults receiving care at Federally Qualified Health Centers. The study enrolls 720 English- or Spanish-speaking adults with PTSD who use these centers as their usual source of care. Researchers aim to see if this short, practical therapy can be effectively delivered within collaborative primary care and improve PTSD and depression outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Written Exposure Therapy (WET), a brief behavioral therapy involving six 30-minute sessions with writing exercises
What this could lead to
If effective, this brief therapy could offer a practical, scalable way to reduce PTSD symptoms in underserved patients who lack access to longer treatments.
What could go wrong
The trial is still testing effectiveness, and results may not generalize beyond community health centers. As a behavioral therapy, benefits depend on patient engagement and therapist delivery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 720 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients will be included if they are 18 years of age or older, speak English or Spanish, have a scheduled or walk-in appointment with a participating primary care provider (PCP), have no obvious physical or cognitive impairment that would make them unable to complete the assessment (as indicated by confusion or inability to understand the questions), and consider the FQHC to be their usual source of care. Exclusion Criteria: * Patients will be excluded if they have active psychosis (as indicated by inability to concentrate, having delusions or hallucinations) or high suicide risk (as indicated by having a current plan or means).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTSD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTSD

Contacts and locations

Locations

  • Bedford Stuyvesant Family Health Center (Main)

    Brooklyn, New York, 11216, United States

  • Bedford Stuyvesant Family Health Center (Sterling and Broadway)

    Brooklyn, New York, 11216, United States

  • Brownsville Health Center (Genesis and Ashford - BGA)

    Brooklyn, New York, 11212, United States

  • Brownsville Health Center (Main)

    Brooklyn, New York, 11212, United States

  • OIC Family Medical Center (Fairview)

    Rocky Mount, North Carolina, 27801, United States

  • OIC Family Medical Center (Happy Hill)

    Rocky Mount, North Carolina, 27804, United States

  • Oak Orchard Health (Pembroke)

    Corfu, New York, 14036, United States

  • Oak Orchard Health Center (Albion)

    Albion, New York, 14411, United States

  • Open Door Family Medical Center (Brewster/Ossining)

    Ossining, New York, 10562, United States

  • Open Door Family Medical Center (Mamaroneck//Port Chester)

    Port Chester, New York, 10573, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.